CoreBiome's key offering is quick and accurate genetic analysis and characterization of communities of microorganisms.
Current applications include gut-microbe science, drug-discovery research, soil-productivity enhancement, and food- and water-quality monitoring, CoreBiome's website says.
"Our goal has been to accelerate discovery of microbiome-based solutions combining genomics and machine learning innovation to help customers leverage that big data and to make world-class microbiome expertise available on-demand," CoreBiome CEO Dan Knights said in a U news release about the deal.
Read the full story in the Star Tribune.